XOMA Royalty (XOMA) Change in Accured Expenses (2010 - 2026)
XOMA Royalty (XOMA) reported Change in Accured Expenses of -$2.6 million for Q1 2026, up 19.51% on a YoY basis from -$2.2 million in Q1 2025, and up 64.24% sequentially from -$7.3 million in Q4 2025.
XOMA Royalty (XOMA) Change in Accured Expenses (2010 - 2026) Analysis & Trends
XOMA Royalty (XOMA) has 17 years of Change in Accured Expenses data on file, last reported at -$2.6 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Accured Expenses rose 19.51% year-over-year to -$2.6 million; the trailing twelve-month figure through Mar 2026 stood at -$10.4 million (down 563.51% YoY), and the FY2025 full-year result was -$10.6 million, down 763.14% from the prior year.
- Change in Accured Expenses climbed to -$2.6 million in Q1 2026, from -$7.3 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $3.1 million in Q1 2023 to a low of -$7.3 million in Q4 2025.
- A 5-year average of -$465250.0 and a median of $38000.0 in 2022 frame the typical range for Change in Accured Expenses.
- Across the five-year window, Change in Accured Expenses surged 9403.23% in 2024 and tumbled 3009.52% in 2025, its largest moves.
- Tracing XOMA's Change in Accured Expenses over 5 years: stood at $1.2 million in 2022, then plunged by 97.52% to $31000.0 in 2023, then surged by 9403.23% to $2.9 million in 2024, then plunged by 349.46% to -$7.3 million in 2025, then surged by 64.24% to -$2.6 million in 2026.
- Business Quant data shows XOMA's Change in Accured Expenses at -$2.6 million in Q1 2026, -$7.3 million in Q4 2025, and $2.9 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 931,000.00 |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -16.82 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -16.74 Mn |
| 10 | XOMA Royalty | 478.42 Mn | 412.34 Mn | - | -2.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.63 Mn |
| Mar 31, 2026 | -2.63 Mn |
| Dec 31, 2025 | -7.35 Mn |
| Dec 31, 2025 | -7.35 Mn |
| Jun 30, 2025 | 2.88 Mn |
| Jun 30, 2025 | 2.88 Mn |
| Mar 31, 2025 | -3.27 Mn |
| Mar 31, 2025 | -3.27 Mn |
| Dec 31, 2024 | 2.95 Mn |
| Dec 31, 2024 | 2.95 Mn |
| Sep 30, 2024 | -2.27 Mn |
| Sep 30, 2024 | -2.27 Mn |
| Jun 30, 2024 | 1.03 Mn |
| Jun 30, 2024 | 1.03 Mn |
| Mar 31, 2024 | -105,000.00 |
| Mar 31, 2024 | -105,000.00 |
| Dec 31, 2023 | 31,000.00 |
| Dec 31, 2023 | 31,000.00 |
| Sep 30, 2023 | 215,000.00 |
| Sep 30, 2023 | 215,000.00 |